TherapeuticsMD, Inc.
TXMD
$1.12
-$0.05-4.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.54% | 35.25% | -97.70% | -98.57% | -98.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.54% | 35.25% | -97.70% | -98.57% | -98.28% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 53.54% | 35.25% | -97.70% | -98.57% | -98.26% |
| SG&A Expenses | -37.19% | -46.71% | -69.94% | -81.53% | -83.02% |
| Depreciation & Amortization | -54.18% | -44.79% | 76.09% | 46.54% | 15.38% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.32% | -46.53% | -65.22% | -78.74% | -81.29% |
| Operating Income | 55.23% | 59.03% | -109.39% | -114.91% | -127.05% |
| Income Before Tax | 64.72% | 69.74% | -109.48% | -116.76% | -137.51% |
| Income Tax Expenses | -46.51% | 27.91% | -- | -- | -- |
| Earnings from Continuing Operations | 65.49% | 69.97% | -109.38% | -116.61% | -137.25% |
| Earnings from Discontinued Operations | 103.22% | 105.08% | -97.50% | -109.18% | -100.86% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.66% | 78.78% | -104.85% | -114.24% | -104.71% |
| EBIT | 55.23% | 59.03% | -109.39% | -114.91% | -127.05% |
| EBITDA | 58.75% | 63.10% | -108.20% | -113.10% | -124.11% |
| EPS Basic | 73.85% | 81.12% | -104.00% | -112.41% | -103.97% |
| Normalized Basic EPS | 50.32% | 58.71% | -106.41% | -110.79% | -122.51% |
| EPS Diluted | 73.30% | 81.25% | -104.73% | -116.25% | -104.26% |
| Normalized Diluted EPS | 50.32% | 58.71% | -107.44% | -113.29% | -131.89% |
| Average Basic Shares Outstanding | 6.10% | 10.58% | 13.65% | 15.73% | 16.77% |
| Average Diluted Shares Outstanding | 6.10% | 10.58% | 9.95% | 11.83% | 12.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |